US-based Cerulean Pharma, a nanopharmaceutical company backed by Lilly Ventures, raises $13m from a consortium of previous backers, bringing the total raised by the drug company to $80m.

US-based broad spectrum antibiotics developer Rib-X Pharmaceuticals withdraws its registration for an $80m IPO.

Novartis, via its Novartis Venture Funds, participates in a $11m Series A round for cancer treatment company Galera Therapeutics.

Singapore-based Pioneer Pharma has invested $2.5m into NovaBay Pharma.

Allergan has acquired US-based SkinMedica for $350m.

GE Healthcare steps up involvement with portfolio company InSightec, investing much of the ultrasound technology company's latest round, with senior GE executives joining the company as chief executive and chairman.

US-based Epic Sciences, a biotech and cancer diagnostics company, raises $13m in Series B financing.

US-based Quanterix, a maker of diagnostic tests, closes its Series C round at $18.5m, a round which included a $15m equity stake from multinational biotechnology company BioMerieux.

Drug company Merck continues its spending via its Global Health Innovation Fund, with a $6m investment into US-based biomedical informatics company Remedy Informatics.

US-based financial services firm Morgan Stanley has led a $15.3m Series E round for US-based NanoString Technologies, a spin out of Seattle-based Institute for Systems Biology.